Connect with us

Politics

Where Presidential Candidate Steve Bullock Stands On Marijuana

Published

on

Steve Bullock announced on May 14, 2019 that he was seeking the 2020 Democratic presidential nomination. He dropped out on December 2.

The Montana governor, who previously served as the state’s attorney general, supports medical cannabis, but his stance on legalizing marijuana for adult use is unclear. NORML gives Bullock a “B” grade based on his record.

This piece was last updated on December 2, 2019 to include the candidate’s statements and policy actions on marijuana since joining the race.

Legislation And Policy Actions

Montana’s medical cannabis program has undergone several revisions since voters first approved it in 2004.

As attorney general and a gubernatorial candidate in 2012, Bullock voiced opposition to a law that repealed the voter-led initiative and replaced it with a more tightly controlled system.

He said he voted in favor of the 2004 initiative and would also be voting to strike down the new law, SB 423, when voters got the opportunity in the form of a veto resolution initiative on the November 2012 ballot. (That measure did not succeed in repealing the law.)

“What we want to do is make sure those in legitimate medical need get the opportunity to get medical marijuana and those that don’t are precluded from doing so,” he said during an October 2012 gubernatorial debate.

“I don’t want unlimited grow operations and things like that. I don’t think anybody does,” he added. “I don’t think we want the chronic pain of ages 19 to 29 be the largest group [of medical cannabis patients]. We can put sideboards on this and we can actually make it as other states have done and it will make a difference.”

Days after that debate, Bullock was asked to respond to criticism from his opponent that he lacked leadership in the regulation of medical cannabis as attorney general. Bullock pushed back, noting that he organized meetings with law enforcement and sent a memo to the legislature outlining areas where he felt the system could be further reformed.

“We were working on solving the issue and we still have to do more to solve the issue,” he said. “We still have to make sure that we have a system where we can closely and tightly regulate it. Those that are entitled to it under the law, we want to get it, but we also don’t want abuses. And we can make that system.”

The year before he came out against the law to scale back the voter-approved medical cannabis system at the gubernatorial debate, Bullock argued in his capacity as attorney general that a lawsuit challenging the reform measure’s constitutionality was baseless.

The law, which was enacted without the then-governor’s signature, was meant to stymie the commercial market, prohibiting large scale manufacturers and shifting to a “grow-your-own” model that allowed registered patients to cultivate marijuana for personal use and let caregivers grow for up to three patients.

Industry advocates filed the lawsuit, calling the new system “unconstitutional.” In response, Bullock said “their arguments are based more on political and policy grounds than on sound constitutional principles.”

“Unfortunately, the narrow door the voters agreed to [in 2004] for compassionate use of medical marijuana was blown open by abuses and commercialization,” his office said at the time.

When that case was eventually settled in 2016, with the state Supreme Court upholding most of the law’s provisions, Bullock came to the defense of patients as governor. He sided with advocates who requested a 14-month delay of the enforcement of the court’s ruling.

“I am concerned about the ability of thousands of patients with serious medical conditions to access a treatment that has been approved by their doctors,” he said in a statement.

Voters approved a separate medical cannabis initiative in November 2016—eliminating patient limits for caregivers and the requirement for a second physician’s opinion before patients with chronic pain could access marijuana.

Bullock signed a bill in May 2017 that made a series of amendments to the new voter-approved initiative, including implementing seed-to-sale tracking systems, adding requirements for testing facilities and imposing fees on providers and dispensaries. It also removed a requirement that parents had to be the caregivers of minors.

Also that year, the Bullock signed a bill to impose the first taxes on medical marijuana sales. Cannabis providers would be taxed four percent on gross sales, dropping to two percent in June 2018.

In 2015, Bullock signed HB 463, a bill to dramatically reform the state’s civil asset forfeiture laws, which are often used against people accused of committing drug offenses. It would require a conviction before police seize the assets of a property owner suspected of engaging in criminal activity.

On The Campaign Trail

Since launching his campaign, Bullock has largely taken a states’ rights approach to his marijuana platform, repeatedly arguing that the federal government should not intervene in state-legal programs.


“I think this should be left up to the states,” he said in July. “I think the federal government should get out of the way and this is a state-by-state decision.”

He made similar remarks in an interview in October, stating that decriminalization “should be a state-by-state decision.”

“We’ve taken some great strides on medical marijuana in Montana, but the federal government needs to get out of the way,” he said.

During a campaign event in Iowa in November, the governor said “I am for medical marijuana.” He again added that the federal government shouldn’t dictate what states do with regard to cannabis policy.

“Gov. Bullock believes the criminalization of marijuana has ruined the lives of too many Americans and cost taxpayers too much money imprisoning non-violent offenders, and supports legalization and taxation of marijuana with appropriate regulations to prevent abuse,” his campaign told USA Today. “The governor will work to remove barriers at the federal level that conflict with states’ decisions to have medical marijuana or legalize it outright.”

At a speech before the National Press Club in August, Bullock noted that people of color are four times more likely to be arrested over marijuana than white people are.

Quotes And Social Media Posts

In April 2017, Bullock criticized the Justice Department under the Trump administration for being out of touch on the issue of cannabis and for indicating that it would crack down on state-legal marijuana programs.

“When it comes to marijuana, and marijuana for medicinal purposes—which Montana has—I think [Attorney General Jeff Sessions] is dang near a decade late,” he said. “That cat is kind of out of the bag. We’ve been spending a lot of time in our legislature saying: Let’s look at our overall correctional system.”

Advocates have also applauded Bullock for standing up for the rights of medical cannabis patients to use and possess firearms.

In a 2011 letter to then-U.S. Attorney General Eric Holder, he wrote that a Bureau of Alcohol, Tobacco and Firearms and Explosives (ATF) memo explicitly stating that medical marijuana patients are disqualified from owning guns even if they use cannabis in compliance with state law “implicates serious legal issues under the Second Amendment, and the equal protection and due process clauses of the Fifth Amendment.” It also “raises serious policy and practical concerns.”

“I am willing and prepared to work constructively with your staff on exploring reasonable solutions to the problem created by the [ATF] letter,” he wrote. “By working creatively and cooperatively, I believe we can find an approach that works for the states that have authorized the use of marijuana for medical purposes.”

“This would be much better than the type of unilateral proclamation represented by the ATF letter, which was issued without any advance notice or discussion with the elected officials who represent more than one-fourth of this nation’s population, and one-third of its states,” he said.

Besides posting about his letter to Holder, Bullock has refrained from posting about cannabis policy on social media.

Personal Experience With Marijuana

It does not appear that the governor has spoken publicly about any personal experience with marijuana. While discussing his support for the 2004 medical cannabis legalization initiative, however, he said that voters “all had somebody in mind,” indicating that he knows people who’ve used cannabis medicinally.

Marijuana Under A Bullock Presidency

Bullock’s lack of commentary on broader marijuana reform casts doubts on whether he’d support wide-ranging legislation to end federal prohibition. It also generally implies that cannabis reform would not be at the top of his agenda if elected.

As other candidates compete to demonstrate a strong interest in the issue, sponsoring or cosponsoring bills to fundamentally change the country’s marijuana laws with some talking about going beyond cannabis in terms of drug policy reform, Bullock stands out for his relative silence.

That said, Bullock has been relatively consistent in his support for patient access to medical marijuana and it appears likely that states with such programs would be protected from federal interference under a Bullock administration.

Where Presidential Candidate Michael Bennet Stands On Marijuana

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Politics

Top IRS Official Says Marijuana Banking Reform Would Help Feds ‘Get Paid’

Published

on

The Internal Revenue Service (IRS) would like to get paid—and it’d help if the marijuana industry had access to banks like companies in other legal markets, an official with the federal department said. She also talked about unique issues related to federal tax deductions for cannabis businesses.

At an event hosted by UCLA’s Annual Tax Controversy Institute on Thursday, IRS’s Cassidy Collins talked about the “special type of collection challenge” that the agency faces when it comes to working with cannabis businesses while the product remains federally illegal.

While IRS isn’t taking a stand on federal marijuana policy, Collins said that the status quo leaves many cannabis businesses operating on a cash-only basis, creating complications for the agency, in part by making it harder for banks to “pay us.”

“The reason why [the marijuana industry is] cash intensive is twofold,” she said. “Number one, a lot of customers don’t want a paper trail showing that they’re buying marijuana, and number two, the hesitancy of banks to allow marijuana businesses to even bank with them.”

Of course, the reason why many financial institutions remain hesitant to take on cannabis companies as clients is because the plant is a strictly controlled substance under federal law.

“There’s been a number of legislative bills that have been introduced—and I am definitely not expressing any opinion personally or on behalf of the IRS about any pending or proposed legislation,” Collins, who is a senior counsel in the IRS Office of Chief Counsel, said. “But it is interesting to note that, if the law changed so that the marijuana businesses could have banks, that would make the IRS’s job to collect [taxes] a lot easier. As part of collection, we want the money. That’s our end goal there.”

A major part of what makes cannabis businesses unique is that they don’t qualify for traditional tax credits under an IRS code known as 280E. That policy “prohibits them from claiming deductions for business expenses because they’re technically being involved in drug trafficking,” Collins explained at the event, from which small excerpts of her comments were reported by Bloomberg.

There are some options available to lessen the burden on marijuana firms, however. At the end of the day, “IRS will work with marijuana companies because, again, we want to get paid,” Collins said.

One of the ways the agency works with marijuana business operators is to have them visit designated IRS “tax assistance centers” that accept cash payments in excess of $50,000. But the official warned businesses to “be prepared to be there for a little while” as the center checks—and double checks—the amount of cash being submitted.

“Revenue officers will assist the marijuana companies in paying us,” she said.

IRS officials could also help cannabis firms by having officials accompany them “to the bank in order to try to help the taxpayer secure a cashier’s payment to pay the IRS, as well as using money orders,” she said, adding that “our revenue officers are are wanting to work with the marijuana companies to help assist them to pay us.”

“When the revenue officers are there in person with the taxpayer, that could potentially help increase the likelihood that the bank will cooperate and help the taxpayer transition into a cashier’s check,” she continued. “And that has been a trend since this first became legal [at the state level], that more and more banks are allowing cannabis companies to bank with them.”

In a report published earlier this year, congressional researchers examined tax policies and restrictions for the marijuana industry—and how those could change if any number of federal reform bills are enacted.

IRS, for its part, said last month that it expects the cannabis market to continue to grow, and it offered some tips to businesses on staying compliant with taxes while the plant remains federally prohibited.

As it stands, banks and credit unions are operating under 2014 guidance from the Financial Crimes Enforcement Network (FinCEN) that lays out reporting requirements for those that choose to service the marijuana industry.

Leaders in both chambers of Congress are working on legalization bills to end federal marijuana prohibition. But stakeholders are hopeful that, in the interim, legislators will enact modest marijuana banking reform. Legislation to protect financial institutions from being penalized for working with cannabis businesses passed the House for the fifth time last month.

Rodney Hood, a board member of the National Credit Union Administration, wrote in a Marijuana Moment op-ed this month that legalization is an inevitability—and it makes the most sense for government agencies to get ahead of the policy change to resolve banking complications.

IRS separately hosted a forum in August dedicated to tax policy for marijuana businesses and cryptocurrency.

Earlier this year, IRS Commissioner Charles Rettig told Congress that the agency would “prefer” for state-legal marijuana businesses to be able to pay taxes electronically, as the current largely cash-based system under federal cannabis prohibition is onerous and presents risks to workers.

Former Treasury Secretary Steven Mnuchin said in 2019 that he’d like to see Congress approve legislation resolving the cannabis banking issue and he pointed to the fact that IRS has had to build “cash rooms” to deposit taxes from those businesses as an example of the problem.

IRS released updated guidance on tax policy for the marijuana industry last year, including instructions on how cannabis businesses that don’t have access to bank accounts can pay their tax bills using large amounts of cash.

The update appears to be responsive to a Treasury Department internal watchdog report that was released earlier in the year. The department’s inspector general for tax administration had criticized IRS for failing to adequately advise taxpayers in the marijuana industry about compliance with federal tax laws. And it directed the agency to “develop and publicize guidance specific to the marijuana industry.”

Luxembourg Set To Become First European Country To Legalize Marijuana Following Government Recommendation

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Luxembourg Set To Become First European Country To Legalize Marijuana Following Government Recommendation

Published

on

Luxembourg is poised to become the first European country to legalize marijuana, with key government agencies putting forward a plan to allow the possession and cultivation of cannabis for personal use.

The ministers of justice and homeland security on Friday unveiled the proposal, which will still require a vote in the Parliament but is expected to pass. It’s part of a broader package of reform measures the agencies are recommending.

Under the marijuana measure, adults 18 and older could grow up to four plants. However, under the non-commercial model that is being proposed, possessing more than three grams in public would still be a civil offense, carrying a fine of €25-500 ($29-581). Currently, the maximum fine for possession is €2,500 ($2,908).

In terms of access, adults would be able to buy and trade cannabis seeds for their home garden.

Justice Minister Sam Tamson said the government felt it “had to act” and characterized the home cultivation policy change as a first step, The Guardian reported.

“The idea is that a consumer is not in an illegal situation if he consumes cannabis and that we don’t support the whole illegal chain from production to transportation to selling where there is a lot of misery attached,” he said. “We want to do everything we can to get more and more away from the illegal black market.”

While limited in scope, the reform would make Luxembourg the first country in Europe to legalize the production and possession of marijuana for recreational use. Cannabis has been widely decriminalized in certain countries in the continent, but it has remained criminalized by statute.

Government sources in Luxembourg told The Guardian that plans are in the works to develop a program where the state regulates the production and distribution of marijuana. Tamson said they are working to resolve “international constraints” before taking that step, however, referring to United Nations treaty obligations that multiple U.S. states and other countries like Canada and Uruguay have openly flouted.

For now, the country is focusing on legalization within a home setting. Parliament is expected to vote on the proposal in early 2022, and the ruling parties are friendly to the reform.

This has been a long time coming, as a coalition of major parties of Luxembourg agreed in 2018 to enact legislation allowing “the exemption from punishment or even legalization” of cannabis.

Meanwhile in the U.S., congressional lawmakers are working to advance legalization legislation. A key House committee recently approved a bill to end marijuana prohibition, and Senate leadership is finalizing a separate reform proposal.

In Mexico, a top Senator said this week that lawmakers could advance legislation to regulate marijuana in the coming weeks. The Supreme Court has already ruled that adults cannot be criminalized over possession or cultivation, but there’s currently no program in place to provide access.

New Bipartisan Marijuana Research Bill In Congress Would Let Scientists Study Dispensary Products

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

New Bipartisan Marijuana Research Bill In Congress Would Let Scientists Study Dispensary Products

Published

on

A bipartisan group of federal lawmakers introduced a bill on Thursday to remove barriers to conducting research on marijuana, including by allowing scientists to access cannabis from state-legal dispensaries.

The Medical Marijuana Research Act, filed by the unlikely duo of pro-legalization Rep. Earl Blumenauer (D-OR) and prohibitionist Rep. Andy Harris (R-MD), would streamline the process for researchers to apply and get approved to study cannabis and set clear deadlines on federal agencies to act on their applications.

“Congress is hopelessly behind the American people on cannabis, and the quality of our research shows why that is an urgent problem,” Blumenauer told Marijuana Moment. “Despite the fact that 99 percent of Americans live in a state that has legalized some form of cannabis, federal law is still hamstringing researchers’ ability to study the full range of health benefits offered by cannabis, and to learn more about the products readily available to consumers.”

“It’s outrageous that we are outsourcing leadership in that research to Israel, the United Kingdom, Canada, and others. It’s time to change the system,” he said.

Late last year, the House approved an identical version of the cannabis science legislation. Days later, the Senate passed a similar bill but nothing ended up getting to the president’s desk by the end of the last Congress. Earlier this year, a bipartisan group of senators refiled their marijuana research measure for the current 117th Congress.

Meanwhile, lawmakers are also advancing a separate strategy to open up dispensary cannabis to researchers. Large-scale infrastructure legislation that has passed both chambers in differing forms and which is pending final action contains provisions aimed at allowing researchers to study the actual marijuana that consumers are purchasing from state-legal businesses instead of having to use only government-grown cannabis.

The new bill filed this week by Blumenauer and Harris, along with six other original cosponsors, would also make it easier for scientists to modify their research protocols without having to seek federal approval.


Marijuana Moment is already tracking more than 1,200 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

It would additionally mandate that the Drug Enforcement Administration (DEA) license more growers and make it so there would be no limit on the number of additional entities that can be registered to cultivate marijuana for research purposes. It would also require the U.S. Department of Health and Human Services (HHS) to submit a report to Congress within five years after enactment to overview the results of federal cannabis studies and recommend whether they warrant marijuana’s rescheduling under federal law.

“The cannabis laws in this country are broken, including our laws that govern cannabis research,” Blumenauer said in remarks in the Congressional Record. “Because cannabis is a Schedule I substance, researchers must jump through hoops and comply with onerous requirements just to do basic research on the medical potential of the plant.”

The new legislation will “both streamline the often-duplicative licensure process for researchers seeking to conduct cannabis research and facilitate access to an increased supply of higher quality medical grade cannabis for research purposes,” he said, adding that expanded studies will help make sure “Americans have adequate access to potentially transformative medicines and treatments.”

For half a century, researchers have only been able to study marijuana grown at a single federally approved facility at the University of Mississippi, but they have complained that it is difficult to obtain the product and that it is of low quality. Indeed, one study showed that the government cannabis is more similar to hemp than to the marijuana that consumers actually use in the real world.

There’s been bipartisan agreement that DEA has inhibited cannabis research by being slow to follow through on approving additional marijuana manufacturers beyond the Mississippi operation, despite earlier pledges to do so.

In May, the agency finally said it was ready to begin licensing new cannabis cultivators. Last week, DEA proposed a large increase in the amount of marijuana—and psychedelics such as psilocybin, LSD, MDMA and mescaline—that it wants produced in the U.S. for research purposes next year.

Under the new House bill, the agency would be forced to start approving additional cultivation applications for study purposes within one year of the legislation’s enactment.

HHS and the attorney general would be required under the bill to create a process for marijuana manufacturers and distributors to supply researchers with cannabis from dispensaries. They would have one year after enactment to develop that procedure, and would have to start meeting to work on it within 60 days of the bill’s passage.

In general, the legislation would also establish a simplified registration process for researchers interested in studying cannabis, in part by reducing approval wait times, minimizing costly security requirements and eliminating additional layers of protocol review.

Read the full text of the new marijuana research bill below:

Click to access medical-marijuana-research-act-hr-5657-text.pdf

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment